

BCR-ABL1 Major Quantitative Testing

Date: September 23rd, 2021

Effective Date: October 20th, 2021

UR Medicine Labs will offer BCR-ABL1 Major (p210) Quantitative testing. BCR-ABL1 quantitative testing is recommended for patients with either chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL).

BCR-ABL1 p210 RT-qPCR will continue to be performed by ARUP Laboratories for 90 days post launch of this in-house assay. The test offered by ARUP Laboratories may have different performance characteristics, and in turn, yield different results. For correlation purposes, tandem reports will be issued through January 17, 2022.

Test code: BCRMQ

Specimen Collection: Lavender (EDTA) blood, Monday - Thursday only.

Note: Specimens must be received within 24 hours of collection due to lability of RNA.

Specimens should be collected by blood draw of at least 5 mL into LAV (EDTA) tube (with minimum of 10 million nucleated cells). It is recommended to minimize sample handling, to store the specimen at 2 to 8 °C, and to ship whole blood specimen on cold packs.

Test Methodology: FDA-cleared Asuragen QuantideX IS qPCR.

Reportable range of quantitation: 0.002%IS (MR4.7) – 50%IS (MR0.3)

Turnaround Time: 3-4 working days upon receipt.

From: Zoltan Oltvai, M.D.

Director of the Molecular Diagnostic Laboratory

UR Medicine Labs

Phone: 585-273-2229

Email: Zoltan_Oltvai@urmc.rochester.edu